Zymeworks Shares Outstanding 2016-2021 | ZYME

Zymeworks shares outstanding from 2016 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Zymeworks Annual Shares Outstanding
(Millions of Shares)
2020 50
2019 38
2018 29
2017 21
2016 13
2015 27
Zymeworks Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 51
2021-03-31 51
2020-12-31 50
2020-09-30 51
2020-06-30 51
2020-03-31 49
2019-12-31 38
2019-09-30 43
2019-06-30 33
2019-03-31 32
2018-12-31 29
2018-09-30 32
2018-06-30 27
2018-03-31 25
2017-12-31 21
2017-09-30 25
2017-06-30 21
2017-03-31 13
2016-12-31 13
2016-09-30 13
2016-06-30 13
2016-03-31 12
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.443B $0.039B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71